Cant argue with you there, the malpractice, lawsuit and a terrible trust in a convertible note guy caused that.
But, essentially, this company started over from scratch and has a chance to be worth quite a bit.
The fact is now that there is cash flow, decent equity holdings and the potential retail and pharma biz this currently has alot more going for it than a normal low priced spec stock.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.